This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D80.3 (Selective deficiency of immunoglobulin G [IgG] subclasses) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | IgG subclass deficiency, selective IgG subclass deficiency, IgG1/IgG2/IgG3/IgG4 deficiency, IgG subclass deficiency (IgGSD, IGGSCD), Selective IgG subclass deficiency, Isolated IgG subclass deficiency, Selective gamma-G globulin deficiency (former name) |
| C. Adult onset | Fairly likely to first manifest in adulthood — IgG2 deficiency in children is often transient, but in adults it is frequently first diagnosed, centered on IgG3 deficiency, on the occasion of chronic sinusitis, recurrent bronchitis, or asthma/COPD exacerbations, and it is the most common phenotype in domestic adult primary immunodeficiency cohorts. |
| 1. History | 1964 four IgG subclasses identified using myeloma proteins → 1970 Schur et al. first report of selective IgG subclass deficiency in patients with recurrent pyogenic infections → 1982 IGHG gene deletions discovered → concept reframed around functional antibody assessment. |
| 2. Causes | Mostly primary (unknown cause); delayed IgG2 maturation in children; accompanies IgA deficiency and ataxia-telangiectasia; secondary — systemic steroids, anticonvulsants, rituximab, protein loss, lymphoid neoplasms, HIV. |
| 3. Genetics | IGHG genes are located at 14q32.33; homozygous IGHG deletions are rare; Gm allotype (G2m(n)) affects IgG2 concentration and polysaccharide response; polygenic, familial aggregation; shares genetic background with IgA deficiency and CVID. |
| 4. General epidemiology | By definition, about 2.5% of healthy people fall below −2 SD; boys and IgG2 predominate in children, women and IgG3 in adults; 66.7% (56/84) of domestic adult primary immunodeficiencies; increased frequency in patients with asthma, COPD, and chronic sinusitis. |
| 5. Pathophysiology | Functional division of labor: IgG1 (protein antigens), IgG2 (polysaccharide antigens), IgG3 (viral and complement activation), IgG4 (chronic antigens); impaired class switching and B-cell maturation → reduced opsonization of encapsulated bacteria and viral neutralization. |
| 6. Symptoms | Recurrent or chronic sinusitis, otitis media, bronchitis, pneumonia; frequent exacerbations of asthma/COPD; bronchiectasis; fatigue; accompanying allergic and autoimmune diseases; many are asymptomatic. |
| 7. Signs | One or more subclasses below −2 SD on 2 or more occasions with total IgG in the normal range; decreased pneumococcal polysaccharide antibody response (about half); mucosal thickening on sinus CT; bronchiectasis on HRCT; obstructive defect on pulmonary function. |
| 8. Screening | No population screening; measure IgG/A/M and IgG1–4 together for recurrent infection, refractory sinusitis, frequent asthma/COPD exacerbations, bronchiectasis of unknown cause, or IgA deficiency; avoid the period of acute infection or systemic steroid use. |
| 9. Diagnosis | Normal IgG, IgA, IgM; one or more subclasses below −2 SD on 2 occasions at least 1 month apart; recurrent infections; exclusion of T-cell defects and secondary causes; functional assessment by protein and polysaccharide vaccine responses; differentiation from CVID and specific antibody deficiency. |
| 10. Treatment | Stepwise approach: control of underlying respiratory disease → vaccination → prophylactic antibiotics → immunoglobulin replacement if functional antibody deficiency accompanies it (IVIG 400–600 mg/kg every 3–4 weeks, SCIG 100–200 mg/kg weekly) followed by reassessment. |
| 11. Prognosis | Usually normalizes by school age in children; commonly persists in adults; some progress to CVID; poor with multiple subclass deficiency or specific antibody deficiency; immunoglobulin replacement reduces infections and antibiotic use. |
| 12. Prevention | No primary prevention; vaccination (pneumococcal, influenza, COVID-19); smoking cessation; minimize repeated systemic steroid use; asthma control; regular follow-up of lung function; surveillance for CVID progression by re-measuring immunoglobulins. |
| 13. References | Current issues in the management of IgG subclass deficiencies in adults with chronic respiratory diseases … and 9 other papers |
The history of IgG subclass deficiency begins with the discovery that IgG is not a single molecule but is composed of four subclasses. In the early 1960s, several research groups used antisera against monoclonal IgG proteins from multiple myeloma patients to confirm that antigenically distinct groups exist among IgG molecules. In 1964, Grey and Kunkel and Terry and Fahey independently reported that IgG is divided into four subclasses, and in 1966, under the World Health Organization (WHO) nomenclature, they were named IgG1, IgG2, IgG3, and IgG4 in order of serum concentration.
Once the subclasses were discovered, it soon became clear that each subclass responds selectively to different antigens. As the concept was established that the response to protein antigens is carried out mainly by IgG1 and IgG3 and the response to bacterial capsular polysaccharides mainly by IgG2, the hypothesis was raised that even when total IgG is normal, lack of a specific subclass could make a person vulnerable to specific pathogens.
In 1970, Schur, Borel, Gelfand, Alper, and Rosen reported in the New England Journal of Medicine "selective gamma-G globulin deficiencies in patients with recurrent pyogenic infections," first systematically showing that recurrent bacterial infections occur in patients with low levels of one or more IgG subclasses even when total IgG is nearly normal. In the late 1970s, Oxelius compiled age-specific IgG subclass reference values in children and reported that IgG2 deficiency is common in children with recurrent respiratory infections, and in 1981 published that infections are frequent in the group with accompanying IgG2 deficiency among IgA-deficient patients.
In 1982, Lefranc et al. reported in Nature healthy individuals who completely lacked a specific subclass because of homozygous deletion of IgG constant region genes (IGHG). This finding showed that the absence of a subclass does not necessarily lead to disease, and became the starting point of a long debate over the clinical significance of IgG subclass deficiency. In the 1980s–1990s, the recognition spread that subclass concentration alone cannot adequately predict susceptibility to infection, and the concept of specific antibody deficiency (SAD), which directly evaluates the specific polysaccharide antibody response, developed in parallel.
Since the 2000s, the ESID clinical working definitions and the IUIS classification of inborn errors of immunity have included "isolated IgG subclass deficiency" as a disease mainly in the category of antibody deficiencies, and the 2015 practice parameter of the American Academy of Allergy, Asthma & Immunology recommended making the functional antibody response, rather than subclass concentration, the key to treatment decisions. In Korea, in 2010 Kim et al. reported that IgG subclass deficiency was the most common phenotype (66.7%) in an adult primary immunodeficiency cohort, and studies of IgG subclass deficiency in patients with chronic airway diseases such as asthma and COPD have since been actively conducted. It is currently managed in Korea as an immunodeficiency disease eligible for rare disease Special Copayment Reduction.
Significance of the conceptual change
The history of IgG subclass deficiency can be described as the process of clarifying the relationship between "laboratory value abnormality" and "clinical immunodeficiency." Initially, decreased subclass concentration itself was regarded as evidence of immunodeficiency and immunoglobulin replacement was widely given, but as cases of asymptomatic deletion and spontaneous recovery in children accumulated, the treatment indication narrowed to patients in whom recurrent infections and a functional antibody defect were confirmed. A dual approach is now established in which subclass measurement serves as a screening tool and the specific antibody response serves as the basis for treatment decisions.
IgG subclass deficiency is divided into primary and secondary according to cause, and at diagnosis secondary causes and cases occurring as part of other immunodeficiency diseases must be excluded.
Primary IgG subclass deficiency
Most are primary deficiencies for which no clear single cause has been identified. An imbalance in subclass-specific class switching or plasma cell differentiation of B cells is thought to underlie it, and familial aggregation and coexistence with IgA deficiency and CVID suggest genetic predisposition. Primary deficiency in adults is generally persistent, and IgG3 deficiency is the most common.
Developmental delay in maturation (children)
IgG1 and IgG3 reach adult levels relatively early, but IgG2 and IgG4 mature late and reach adult levels only after school age. For this reason, decreased IgG2 in infants and young children is to a large extent physiologic delayed maturation or transient deficiency, and often normalizes with growth. It is more common in boys among children.
Part of other primary immunodeficiencies
IgG subclass deficiency accompanies selective IgA deficiency (especially with IgG2 and IgG4 deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, 22q11.2 deletion syndrome, chronic mucocutaneous candidiasis, and others. IgG subclass deficiency may also appear first as an early stage of CVID.
Secondary causes
Clinical significance
Repeated use of systemic steroids in asthma patients can temporarily lower IgG for several weeks, so drug use at the time of measurement must be checked. In contrast, high-dose inhaled steroids are reported to have no marked effect on serum IgG. The diagnosis of primary deficiency is made after these secondary factors have been systematically excluded.
Differentiating the cause in practice
When decreased subclass levels are confirmed, secondary causes are first screened with albumin, urine protein, protein electrophoresis, medication history, and HIV testing. Decreases related to steroid use often recover within weeks to months after discontinuation, so this is checked with re-measurement. If lymphoid neoplasm is suspected, serum free light chains and immunofixation electrophoresis are added. When it appears as part of another primary immunodeficiency, evaluation and management of the underlying disease take priority.
IgG subclass deficiency is mostly understood as a polygenic complex disease that does not follow Mendelian inheritance. However, in some rare cases a structural deletion of the immunoglobulin heavy chain constant region genes is the direct cause.
IGHG gene structure
The constant regions of the four IgG subclasses are located at the immunoglobulin heavy chain (IGH) locus on the long arm of chromosome 14 (14q32.33), arranged in the 5′ to 3′ direction in the order IGHM, IGHD, IGHG3, IGHG1, IGHEP1, IGHA1, IGHGP, IGHG2, IGHG4, IGHE, IGHA2. B cells produce a specific subclass by class switch recombination at the switch regions between these constant region genes.
IGHG gene deletions
In 1982, Lefranc et al. reported healthy individuals with homozygous deletion of several constant region genes, including IGHG1, IGHG2, IGHG4, and IGHA1. In these large-deletion cases, symptoms were often absent or mild despite the complete absence of the subclass concerned, showing the possibility of compensation by other subclasses and the clinical heterogeneity of subclass absence. These deletions are inherited in an autosomal recessive manner but are very rare.
Gm allotype
The IgG constant region has Gm allotypes, genetic polymorphisms that differ among population groups. In particular, the G2m(n) (G2m23) allele is associated with higher serum IgG2 concentration and a better response to pneumococcal and Haemophilus polysaccharide antigens, and in its absence there is a tendency toward decreased IgG2 and reduced polysaccharide response. This means that reference values for subclass concentration may differ by race.
Immune regulatory genes and shared predisposition
IgG subclass deficiency, selective IgA deficiency, and CVID are sometimes found together in the same family, and a shared haplotype in the MHC region and TNFRSF13B (TACI) variants are cited as shared predisposition. Familial IgG3 deficiency cases have also been reported in Korea and abroad. However, in most primary IgG subclass deficiency no single causative gene has been identified.
Use of genetic testing
Genetic testing is not needed for the diagnosis of typical IgG subclass deficiency. In atypical presentations such as early-onset severe infection, lymphoproliferation, multiple autoimmunity, or CVID in the family, an inborn errors of immunity gene panel can exclude other causes, such as CVID-related genes and ataxia-telangiectasia (ATM).
Genotype-phenotype relationship
Clinical features differ greatly even among individuals with the same IGHG deletion or Gm allotype. Compensatory increase of other subclasses, the role of mucosal IgA, innate immune function, and the degree of environmental pathogen exposure are understood to modulate the phenotype. Therefore, it is difficult to predict the clinical course from genetic information alone, and judgment should integrate repeatedly measured subclass concentrations, the functional antibody response, and the actual infection history.
The exact prevalence of IgG subclass deficiency is hard to estimate because of the statistical nature of the definition and differences in test methods and reference values. If deficiency is defined as below −2 SD of the age-specific reference value, about 2.5% of the healthy population falls under "deficiency" by definition, so it is important to distinguish asymptomatic decrease from clinically meaningful deficiency.
Immunodeficiency registry data
The proportion of IgG subclass deficiency among patients with predominantly antibody deficiency (PAD) differs greatly by registry system. It was reported as about 25% of PAD in the Rochester Epidemiology Project in the US, about 1.3% in the US USIDNET registry, and about 13.2% in Japan (2011). In Korea, in 2010 Kim et al. reported that 56 (66.7%) of 84 adult primary immunodeficiency patients had IgG subclass deficiency, the most common primary immunodeficiency phenotype in Korean adults.
Age and sex
In children, boys and IgG2 deficiency predominate and it is often transient. In adults, in contrast, women are more numerous and IgG3 deficiency is reported as the most common form. In the cohort of 78 adults analyzed by Khokar and Gupta as well, IgG3 deficiency, alone or together with other subclasses, was the most common. IgG4 deficiency is often below the detection limit even in healthy people, so its clinical significance alone is uncertain.
Association with chronic airway disease
Growing recognition of immunodeficiency in adults
In international registry data, the share of adults among primary immunodeficiency patients continues to grow, and mild antibody deficiencies such as IgG subclass deficiency account for a substantial part of adult-onset diagnoses. This is interpreted as the result of expanded immunologic evaluation in respiratory and allergy practice.
Caveats in interpreting epidemiological data
Study populations (children/adults, general population/patients with respiratory disease), test methods, reference values, and the definition of deficiency (single/repeated measurement) differ from study to study, which limits comparison of prevalence. In particular, studies defining deficiency from a single measurement may overestimate prevalence by including transient decreases. Domestic data come mainly from university hospital allergy and respiratory clinic-based cohorts, so they reflect the characteristics of symptomatic adult patient groups rather than the prevalence in the general population.
The four IgG subclasses share about 90% or more of their amino acid sequence, but they differ in the length and flexibility of the hinge region and in their binding to Fc receptors and complement C1q, and so carry out different immune functions. Because of this division of function, even when total IgG is normal, deficiency of a specific subclass leaves a gap in defense against specific pathogens.
Characteristics and functions by subclass
| Subtype | Proportion of total IgG | Main function |
|---|---|---|
| IgG1 | About 60–70% | Mainstay of the response to protein antigens (toxoids, viral proteins); strong FcγR binding, complement activation |
| IgG2 | About 20–25% | Response to bacterial capsular polysaccharide antigens (pneumococcus, Haemophilus); weak complement activation |
| IgG3 | About 5–8% | Early response to respiratory viruses, etc.; strongest complement activation; short half-life of about 7 days |
| IgG4 | About 2–6% | Increases with repeated or chronic antigen exposure; almost no complement activation; anti-inflammatory role |
Mechanism of deficiency
Subclass-specific production is regulated by class switch recombination in B cells and the cytokine environment that induces it, T-cell helper signals (CD40L), and BAFF/APRIL–TACI signaling. In primary IgG subclass deficiency, reduced efficiency of switching to specific switch regions, impaired memory B-cell formation, and imbalance in plasma cell differentiation are presumed to be involved. In children, immaturity of splenic marginal zone B cells weakens the T-cell-independent response to polysaccharide antigens, so IgG2 production matures late.
Mechanism of susceptibility to infection
IgG2 deficiency weakens opsonization and complement-mediated killing of encapsulated bacteria such as pneumococcus, Haemophilus influenzae, and meningococcus, causing sinusitis, otitis media, and pneumonia. IgG3 deficiency weakens early neutralization and complement activation of respiratory viruses and bacteria, causing recurrent upper and lower respiratory tract infections. IgG1 deficiency often leads to decreased total IgG, so the boundary with CVID is blurred.
Importance of functional antibody defects
Even if subclass concentration is low, the infection risk may not be great if the specific antibody response is normal, and conversely, even if subclass concentration is normal, infections recur if the response to polysaccharide antigens is lacking (specific antibody deficiency). In adult cohorts, about half of IgG subclass deficiency patients (56% in the Khokar study) showed a decreased pneumococcal antibody response, and whether this accompanies it determines the clinical course. In addition, recurrent infection and inflammation of the airways cause exacerbations of asthma and COPD, mucus hypersecretion, and changes in airway structure, forming a vicious cycle leading to bronchiectasis.
Interaction with IgA deficiency
The constant region genes of IgG2 and IgG4 and of IgA1 and IgA2 are adjacent at the IGH locus, and class switching to them shares similar signaling pathways. Therefore, IgA deficiency and IgG2 deficiency often accompany each other, and in this combination mucosal defense (secretory IgA) and systemic polysaccharide antibody defense (IgG2) are weakened at the same time, so the risk of recurrent respiratory infections and bronchiectasis is greatest.
The clinical features of IgG subclass deficiency are highly varied, showing a wide spectrum from lifelong asymptomatic cases to recurrent severe infections leading to chronic lung damage. Symptoms are mainly concentrated in the respiratory tract.
Recurrent respiratory infections
Frequent exacerbations of chronic airway disease
In asthma patients, frequent exacerbations triggered by infection and a severe asthma pattern that is difficult to control even with high-dose treatment may appear. In a domestic study, asthma patients with IgG subclass deficiency experienced an average of about 2–3 exacerbations per 6 months, and forced expiratory volume in 1 second (FEV₁) was reduced to about 60–70% of predicted. In COPD patients, the frequency of acute exacerbations and hospitalization increases.
Bronchiectasis-related symptoms
When recurrent infections become prolonged, chronic cough, large amounts of purulent sputum, hemoptysis, and exertional dyspnea appear.
Systemic symptoms
Reduced quality of life, such as chronic fatigue due to recurrent infections, reduced work and study capacity, and frequent absences, is commonly reported.
Symptoms related to comorbid diseases
Asymptomatic deficiency
Many of the subclass decreases found incidentally on health checkups or tests for other purposes are asymptomatic, and isolated IgG4 decrease in particular is mostly without clinical significance. Therefore, the presence of symptoms and the functional antibody response are the key to diagnostic and therapeutic decisions.
Differences by age and subclass
In children, recurrent otitis media, sinusitis, and pneumonia related to IgG2 deficiency mainly appear and tend to improve with growth. In adults, chronic sinusitis, recurrent bronchitis, and asthma/COPD exacerbations related to IgG3 deficiency are the main features. If severe infection, opportunistic infection, lymphadenopathy, splenomegaly, or unexplained diarrhea appear, a more severe immunodeficiency such as CVID should be suspected.
Objective findings in IgG subclass deficiency can be divided into immunologic test findings and changes in respiratory structure and function due to recurrent infection.
Physical examination findings
Immunologic test findings
Imaging findings
Pulmonary function findings
When asthma or COPD accompanies it, obstructive ventilatory defect, bronchodilator responsiveness, and a positive methacholine bronchial provocation test may appear, and a pattern of progressive decline in lung function with recurrent infections is observed. The mean FEV₁ in domestic asthma cohorts with IgG subclass deficiency was about 59–73% of predicted.
Microbiological findings
Pneumococcus, Haemophilus influenzae, Moraxella, and others are repeatedly isolated from sputum or bronchoalveolar lavage fluid cultures, and Pseudomonas aeruginosa may be isolated when bronchiectasis progresses.
Cautions in interpreting tests
Subclass concentrations differ greatly with the test method and reagents, so follow-up tests should be done at the same laboratory whenever possible. Measurements during acute infection, systemic steroid use, immunoglobulin administration, or protein-losing states can distort results. In addition, values below the detection limit for IgG4 are common even in healthy people, so they are not used alone as evidence of deficiency.
Screening the general population for IgG subclass deficiency is not recommended. By definition, a proportion of healthy individuals are classified as deficient, and asymptomatic reductions require no treatment. Instead, targeted testing in clinically suspicious situations is recommended.
Situations in which testing is recommended
Testing method
Measure IgG1 to IgG4 simultaneously together with serum IgG, IgA, and IgM. Measurement is performed by nephelometry or turbidimetry, and results must always be compared with the age-specific reference ranges of the laboratory concerned. If the sum of the four subclasses differs greatly from total IgG, suspect measurement error.
Timing considerations
Concurrent functional screening
Current guidelines recommend evaluating the specific antibody response to polysaccharide antigens in patients with recurrent infections, regardless of IgG subclass or IgA levels. Pneumococcal serotype-specific antibodies are measured by the WHO standard ELISA or multiplex fluorescent bead assay (Luminex), but in Korea access to commercial testing is limited, making accurate diagnosis of specific antibody deficiency difficult. Given these limitations, consider evaluation through a specialized testing facility when possible.
Follow-up according to screening results
If screening confirms reduced subclasses, explanation and observation are sufficient when asymptomatic; when symptomatic, proceed to the diagnostic stage, including repeat measurement and evaluation of the specific antibody response. In addition, even if IgG subclasses are normal, if recurrent infections persist, vaccine response testing should be performed to exclude specific antibody deficiency. This stepwise approach reduces unnecessary immunoglobulin therapy and helps identify patients who actually need treatment.
The diagnosis of IgG subclass deficiency is made by integrating ① clinical susceptibility to infection, ② reduced subclasses confirmed by repeat measurement, ③ exclusion of other immunodeficiencies and secondary causes, and ④ evaluation of the functional antibody response.
Diagnostic criteria (based on the ESID clinical working definitions)
When IgA deficiency coexists, it is classified separately as “IgG subclass deficiency with IgA deficiency,” and the risk of infection is higher.
Step 1: Confirm immunoglobulins and subclasses
Measure IgG, IgA, IgM, and IgG1–4 twice at an interval of at least 1 month. Check for secondary causes such as protein loss (albumin, urine protein), drugs (systemic steroids, anticonvulsants, rituximab), and lymphoproliferative malignancies.
Step 2: Evaluate the functional antibody response
Step 3: Evaluate cellular immunity and differential diagnosis
Evaluate T, B, and NK cell counts and B-cell subsets (such as switched memory B cells) by flow cytometry. The differential diagnosis includes CVID (reduced total IgG and defective antibody response), specific antibody deficiency (normal subclasses), transient hypogammaglobulinemia of infancy, ataxia-telangiectasia, 22q11.2 deletion syndrome, and secondary hypogammaglobulinemia.
Step 4: Evaluate comorbidities and organ damage
Common pitfalls in diagnosis
Common errors include diagnosing on a single measurement, applying adult reference values to children, and interpreting values obtained immediately after steroid use. In addition, judging the indication for immunoglobulin replacement on subclass deficiency alone is inconsistent with current guidelines. Conversely, omitting functional antibody evaluation because the subclasses are normal may miss specific antibody deficiency.
Treatment of IgG subclass deficiency is approached in stages according to symptom severity and the presence of a functional antibody defect. Asymptomatic deficiency is not treated; in symptomatic patients the goals are to reduce infection frequency and prevent chronic lung damage.
Step 1: Optimal control of underlying disease
Treat asthma, allergic rhinitis, chronic sinusitis, and COPD aggressively. In asthma, control centers on inhaled steroids, and because repeated short courses of systemic corticosteroids lower IgG for several weeks, minimize them where possible. Long-term oral steroids lower IgG significantly, so consider alternatives such as biologics. When bronchiectasis coexists, add airway clearance therapy and pulmonary rehabilitation.
Step 2: Vaccination
Step 3: Infection treatment and prophylactic antibiotics
For respiratory bacterial infections, use antibiotics early and for a sufficient duration, and identify the causative organism by sputum or bronchoalveolar lavage culture to give targeted therapy. For recurrent infections, administer prophylactic antibiotics such as azithromycin, trimethoprim-sulfamethoxazole, or amoxicillin, either seasonally or continuously, and monitor for the emergence of resistance.
Step 4: Immunoglobulin replacement therapy (IgRT)
Consider in patients whose recurrent or severe infections persist despite prophylactic antibiotics and control of underlying disease, and in whom a specific antibody response defect has been confirmed.
Treatment of comorbid diseases
Autoimmune diseases and allergic diseases follow their respective standard treatments. When B-cell-targeted therapy is required, monitor for worsening hypogammaglobulinemia.
Evaluation of treatment effect
Record the annual number of infections, days of antibiotic use, number of asthma or COPD exacerbations, hospitalizations, days of work missed, and changes in pulmonary function before and after treatment to evaluate the effect objectively. During immunoglobulin replacement, check the trough IgG level, and if infections persist, consider increasing the dose or shortening the dosing interval. If the effect is inadequate or new findings appear, re-evaluate for progression to CVID or similar conditions.
The prognosis of IgG subclass deficiency varies greatly depending on the age of onset, the number and types of deficient subclasses, the presence of a specific antibody response defect, and the presence of chronic airway disease.
Course in children
IgG subclass deficiency in children, especially IgG2 deficiency, often reflects delayed maturation of the immune system, and a high proportion normalize around school age. In such cases the frequency of infection also decreases. However, some persist or progress to other antibody deficiencies. In a study that followed 24 children with IgG subclass deficiency for a mean of 40 months, 4 progressed to CVID.
Course in adults
IgG subclass deficiency diagnosed in adults is usually persistent. Cases of progression to CVID over 2–15 years have been reported when IgG subclass deficiency coexists with symptomatic IgA deficiency in adults, so periodic re-measurement of immunoglobulins is needed. Infection frequency and severity are higher when multiple subclasses are deficient simultaneously and when specific antibody deficiency coexists than with single subclass deficiency.
Respiratory prognosis
With prolonged recurrent infections, bronchiectasis and decline in pulmonary function may progress, and significant declines in pulmonary function have been reported even during treatment. In COPD patients, IgG subclass deficiency is associated with increased risk of exacerbations and hospitalization, and some studies have observed higher 1-year mortality in COPD patients with IgG1 deficiency. In asthma, increased exacerbation frequency and poor control determine the prognosis.
Treatment response
In appropriately selected patients, immunoglobulin replacement therapy reduces infection frequency, antibiotic use, hospitalizations, and days of work missed, and improves quality of life. In a Swedish long-term follow-up study of 350 adults, days of infection and antibiotic use decreased after replacement therapy, and in a cohort of 78 adults, infections and antibiotic requirements also decreased after immunoglobulin treatment. Some patients remain stable even after treatment is discontinued.
Summary
Most asymptomatic and mild patients have a favorable course, and life expectancy is not greatly affected. However, in symptomatic patients, preventing irreversible lung damage through early diagnosis and appropriate treatment is the key to improving long-term prognosis.
Summary of prognostic factors
Factors associated with poor prognosis include multiple subclass deficiency, coexisting specific antibody deficiency, coexisting IgA deficiency, recurrent severe infections with early onset, the presence of bronchiectasis, coexisting severe asthma or COPD, and diagnostic delay. In patients with these factors, it is desirable to perform immunological and respiratory follow-up at shorter intervals and to adjust treatment intensity actively.
There is no way to prevent the occurrence of primary IgG subclass deficiency itself. Prevention centers on avoiding infection and chronic lung damage, avoiding secondary deficiency, and early detection of progression to more severe immunodeficiency.
Primary prevention: avoiding secondary deficiency
Secondary prevention: infection prevention
Tertiary prevention: monitoring for organ damage and progression
Family management
IgG subclass deficiency, IgA deficiency, and CVID can be found together within families, so immunoglobulin testing may be recommended for family members with recurrent infections. Through such systematic management, irreversible respiratory complications can be prevented and unnecessary treatment avoided in symptomatic patients.
Key points of patient education
Educate patients about the nature and course of the disease, early recognition of infection symptoms and early medical consultation, the vaccination schedule, the importance of adherence to inhaled therapy, and the need to consult their physician when systemic steroids are used. Patients receiving immunoglobulin replacement therapy need education on adhering to the dosing schedule, recognizing and reporting adverse reactions, and the self-administered subcutaneous injection method. Such education improves infection prevention and treatment adherence, thereby improving long-term prognosis.
Jang JH, Kim JH, Park HS. Current issues in the management of IgG subclass deficiencies in adults with chronic respiratory diseases. Allergy, Asthma & Immunology Research. 2023;15(5):562–579. DOI: 10.4168/aair.2023.15.5.562.
Schur PH, Borel H, Gelfand EW, Alper CA, Rosen FS. Selective gamma-G globulin deficiencies in patients with recurrent pyogenic infections. New England Journal of Medicine. 1970;283(12):631–634. DOI: 10.1056/NEJM197009172831205.
Lefranc MP, Lefranc G, Rabbitts TH. Inherited deletion of immunoglobulin heavy chain constant region genes in normal human individuals. Nature. 1982;300(5894):760–762. DOI: 10.1038/300760a0.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Frontiers in Immunology. 2014;5:520. DOI: 10.3389/fimmu.2014.00520.
Kim JH, Park HJ, Choi GS, et al. Immunoglobulin G subclass deficiency is the major phenotype of primary immunodeficiency in a Korean adult cohort. Journal of Korean Medical Science. 2010;25(6):824–828. DOI: 10.3346/jkms.2010.25.6.824. PMID: 20514300.
Khokar A, Gupta S. Clinical and immunological features of 78 adult patients with primary selective IgG subclass deficiencies. Archivum Immunologiae et Therapiae Experimentalis. 2019;67(5):325–334. DOI: 10.1007/s00005-019-00556-3. PMID: 31363786.
Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clinical & Experimental Immunology. 2010;159(3):344–350. DOI: 10.1111/j.1365-2249.2009.04062.x.
Olinder-Nielsen AM, Granert C, Forsberg P, Friman V, Vietorisz A, Björkander J. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scandinavian Journal of Infectious Diseases. 2007;39(1):44–50. DOI: 10.1080/00365540600951192. PMID: 17366012.
Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy and Clinical Immunology. 2015;136(5):1186–1205.e78. DOI: 10.1016/j.jaci.2015.04.049.
Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: a review of evidence. Journal of Allergy and Clinical Immunology. 2017;139(3S):S1–S46. DOI: 10.1016/j.jaci.2016.09.023.